Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases.

The company reported a 95.2% decline in consolidated net profit to Rs 31.40 crore despite of 15.8% jump in net sales to Rs 3,910.10 crore in Q1 FY26 over Q1 FY25.

Shares of Biocon rose 0.31% to Rs 359.70 on the BSE.

Powered by Capital Market - Live News